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Abstract
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder
characterized by extensive memory loss and cognitive deficits, which occur due to severe
neuronal loss. Two hallmark lesions, intracellular neurofibrillary tangles composed of
hyperphosphorylated tau and extracellular neuritic plaques formed by the aggregation of
amyloid-β (Aβ), are responsible for the progressive neuronal loss seen in AD brains.
Neurotoxic Aβ aggregates are also known to cause inflammation within the brain. It has
recently come to light that severe and acute inflammation, such as seen in traumatic brain
injury (TBI), may also lead to AD-type dementia. This has raised the question whether
some of the pro-inflammatory mediators released from activated microglial cells could
play a role in promoting the aggregation of Aβ and subsequent plaque formation. We
hypothesize that a small family of cysteine rich, pro-inflammatory proteins called
Granulins (Grns), which have been implicated in both AD and frontotemporal dementia
(FTD), modulate Aβ aggregation. Based on the data obtained in our lab on GRN-3
protein, we have focused on P43LGRN-3, a missense mutant of GRN-3, which has been
implicated in pathology. P43LGRN-3 was recombinantly expressed in E. coli, purified,
and characterized by biochemical and biophysical tools. The effect of P43LGRN-3 on the
binding and aggregation of Aβ was investigated via co-incubation experiments. The
collected data suggest that monomeric P43LGRN-3 is largely similar to wild type GRN-3
(wt-GRN3) both structurally and functionally, and suggests the possible differences
between the mutant and the wild-type protein could be more prominent with the
precursor protein, progranulin. These data are presented and discussed.
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Chapter 1 - Introduction
Alzheimer’s disease (AD) is an irreversible and progressive disease characterized
by behavioral changes, memory loss, impaired judgment, and loss of cognitive function
in patients above 60 years of age (1). AD is the most common among many
neurodegenerative disorders that lead to dementia, being responsible for approximately
60-80% of the cases. The National Institute on Aging estimates that nearly 5.2 million
Americans suffer from the disease, making AD the sixth leading cause of death in the
United States. As life expectancy continues to increase, a dramatic escalation in the
prevalence of AD is also expected, as there will be more individuals living past 65 years
of age (2).
The aforementioned pathological traits of AD are caused by the progressive loss
of neurons seen in AD brains. Two hallmark lesions cause this acute neuronal death,
namely intracellular neurofibrillary tangles composed of hyper-phosphorylated tau
protein and extracellular neuritic plaques, which are deposited on the brain due to the
aggregation of a polypeptide called amyloid-β (Aβ). The aggregates of Aβ are known to
trigger neurotoxicity. Aβ aggregates are also known to cause inflammation in the brain,
whose mechanism has been widely investigated.
Increasing evidence in recent years has indicated that acute inflammatory
reactions themselves may play a part in inducing the aggregation of Aβ, thereby
triggering a vicious cycle of inflammation and aggregation. Evidence for this comes
primarily from clinical studies on patients suffering from traumatic brain injury, who
show AD symptoms sometimes within hours of sustaining the injury (5). In this context,
pro-inflammatory mediators released by activated microglial cells may play an important
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role (3). One such pro-inflammatory mediator that is released is a family of small,
cysteine rich proteins called Granulins (GRNs). Granulins are cleaved from a larger
precursor molecule that is anti-inflammatory in nature, called Progranulin (PGRN). The
Progranulin protein is composed of 7.5 tandem repeats of different Granulin proteins (17) and Paragranulin (4). Granulin 3 (GRN-3) in particular has been shown experimentally
to be pro-inflammatory in nature and has been previously characterized in the Rangachari
lab. To further investigate the properties and potential role of Granulins in AD, a mutant
form of GRN-3, P43LGRN-3, was chosen as this missense mutation has been implicated
in frontotemporal dementia (FTD). Furthermore, based on the analyses by structural
modeling, the P43L mutation is predicted to be pathogenic due to the destabilizing effect
on protein structure and therefore function (30).
This honors thesis work involves the recombinant expression and characterization
of P43LGRN-3 in E. coli, and the investigation of its further effect on Aβ aggregation.
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Chapter 2 – Background
2.1 Amyloid-β and AD
AD is a debilitating neurodegenerative disease that results in declining cognitive
function, loss of social appropriateness, and memory impairments. Based on genetic
studies, animal modeling, and various biochemical data, it has been suggested that the
aggregation of amyloid-β is responsible for the etiology of AD (6). As mentioned above,
the senile or neuritic plaques characteristic of AD are primarily composed of extracellular
deposits of Aβ peptides, which are formed via the proteolysis of a ubiquitous precursor
protein called β-amyloid precursor protein (APP) (7,8). It has been observed that
mutations in APP or presenilin genes that lead to overexpression of Aβ are seen in many
familial forms of AD (9,10). Furthermore, individuals with Down syndrome who possess
three copies of chromosome 21 – the chromosome housing the APP gene - develop
pathologic symptoms of early-onset AD (10).
The monomeric protein has a high propensity for aggregation into oligomers and
fibrils, which are known to be neurotoxic (11). However, it has been observed that
cognitive decline occurs prior to the accumulation of plaques in transgenic mouse
models, suggesting that low molecular weight soluble oligomers are the primary
neurotoxic agents in AD pathology (12). Aβ aggregates are also known to induce
inflammatory responses in which activated microglial cells release various cytokines,
chemokines, along with other toxic species leading to neuronal death (13,14). The exact
mechanism responsible for microglial activation and the subsequent release of neurotoxic
pro-inflammatory mediators is unknown.
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Conversely, there is evidence that suggests neuroinflammation as the primary
cause for the onset of AD and of Aβ aggregation. Clinical studies have revealed increased
levels of inflammatory proteins such as IL-6 present in the brain and plasma prior to the
onset of dementia, suggesting that central nervous system (CNS) inflammation may be
involved in the pathogenesis of AD (23). Furthermore, several more studies have shown
the efficacy of prolonged use of non-steroidal anti-inflammatory drugs (NSAIDS) at
reducing the risk of AD (24). It is believed that a subset of these drugs is responsible for
selectively inhibiting the production of Aβ42 peptides, the isomeric form of Aβ with the
highest propensity to form aggregates (25,26). In this context, some external event such
as a physical head injury/TBI or a severe infection acts as a stimulus for the initiation of
the inflammatory cascade. In fact, a pathological link between TBI and AD onset is
suspected based on the finding that up to 30% of patients who die following TBI have
extracellular Aβ plaques strikingly similar to those seen in AD (27). These TBIassociated plaques can develop within hours after sustaining the injury, leaving the brain
in a chronic state of inflammation thereby advancing the onset and progression of
sporadic AD (5). The mechanism by which pro-inflammatory mediators released by the
inflammatory cascade trigger initial Aβ aggregation remains unknown. This work is
focused on reducing this knowledge gap by investigating whether there are direct
interactions between Aβ and P43LGRN-3, which may potentially result in GRNs being
established as key players in the molecular link between acute inflammation and AD.
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2.2 Granulins and Neuroinflammation
As mentioned previously, Granulins are small, approximately 6 kDa, proteins that
possess a motif of 12 cysteines consisting of four central pairs flanked by a single pair on
the N- and C- termini (15). GRNs are released following the proteolytic cleavage of a
precursor protein called progranulin (PGRN) by proteases like neutrophil elastase at
linker regions between the GRN domains (4) (Figure 1). Human PGRN consists of seven
and a half tandem repeats of Granulin domains (GRNs 1-7, and Paragranulin) and is
known to have several biological functions including growth factor like activities,
modulation of immune responses, wound repair, and neuronal effects. PGRN is
overexpressed in tumors, including carcinomas, gliomas, and sarcomas (16,17,18), and is
also believed to modulate cell proliferation pathways in tumor and neuronal cells (19,20).

Figure 1: The Domain Structure of PGRN. The boxes indicate the individual GRN
domains (1-7) with the amino acid sequence and putative disulfide-bonding pattern of GRN-3
below. The scissors denote the elastase cleavage sites. The asterisks denote linker regions
where proteolytic cleavage occurs. The highlighted box around the Proline residue in the
amino acid sequence indicates the position of the P43LGRN-3 mutation.

PGRNs and GRNs also play a role in neurodegeneration. It is known that
mutations in the PGRN gene, located on chromosome 17, have been implicated in
frontotemporal lobar dementia (FTLD) (21). FTLD is a neurodegenerative disorder
characterized by behavior modification and altered personality; it is the second most
5
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common presenile form of dementia after AD (22). More importantly, expression of
PGRN as well as of the proteases that cleave it is elevated in microglial cells surrounding
the senile plaques in AD patients. Consequently, the pro-inflammatory GRNs (1-7) that
are secreted from microglial cells during inflammation are up-regulated in cases of TBI.
Interestingly, PGRN inhibits the spreading of pro-inflammatory cytokines, while the
individual GRNs stimulate the secretion of interleukin-8, thereby initiating an immune
response. In other words, the full length PGRN protein has been implicated to be antiinflammatory, while the GRNs are thought to be pro-inflammatory in nature (19,7). We
hypothesize that acute inflammation triggered by other factors, such as TBI, activate
microglial cells responsible for the cleavage of PGRN into the pro-inflammatory GRNs
(4). Once secreted, these GRNs could interact with extracellular Aβ potentially
augmenting its aggregation and therefore, modulating the onset of AD.

2.3 Why P43LGRN-3?
The physiological roles of individual GRN peptides are largely unknown at
present and no concerted effort has been made to determine the activity of all seven.
However, various partial characterizations have yielded information regarding a few.
GRN-6 was found to be mitogenic for glioma cell lines and GRN-4 showed both
mitogenic and growth inhibitory activities (17, 4). More promising, GRN-3 is suspected
to stimulate interleukin-8 secretions thereby exerting pro-inflammatory effects in vivo
(4). Furthermore, due to the incidence of PGRN mutations seen in FTLD patients, several
mutations have been investigated. The majority of PGRN mutations are nonsense
mutations resulting in mRNA decay and therefore decreased levels of PGRN protein, but
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there are some missense mutations that occur within the signal sequence and the mature
PGRN peptide (29). Two such missense mutations, p.Pro248Leu and p.Arg432Cys, have
been found to drastically decrease the secretion of PGRN despite being actively
expressed, with the P248L mutation reducing secretion up to 70%. The implications of
decreased secretion of PGRN are unknown but it has been suggested that restoration of
peptide levels to normal in cases with the above mentioned mutations may be a sufficient
method for delaying onset or progression of AD (29). The p.Pro248Leu and p.Arg432Cys
missense mutations have also been predicted to be pathogenic based on structural
modeling. The Pro248Leu mutation, also referred to as P43LGRN-3, is suspected to have
a significant destabilizing effect on the GRN-3 domain, thereby drastically affecting
protein function (30). This conclusion is based on the probability of structure disruption
based on location of the mutation within a loop connecting two β-hairpins (30).

2.4 Hypothesis and Research Objectives
We hypothesize that the P43L mutation located in the GRN-3 sequence will lead
to structural changes within the protein as compared to the wild-type GRN-3. This
purpose will be investigated through the scope of the following objectives:
1) Expression of P43LGRN-3 in E. coli cells
2) Purification using affinity chromatography and high performance liquid
chromatography (HPLC)
3) Characterization of the biophysical properties
4) Investigating the effect of P43LGRN-3 on amyloid-β aggregation and binding
5) Comparison of P43LGRN-3 characteristics to that of wild-type GRN-3
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Chapter 3 – Materials and Methods

3.1 Cloning and Expression of Human P43LGRN-3 in E. coli.
The P43LGRN-3 cDNA was commercially synthesized (Genewiz Inc.) and
cloned into pET32b plasmid using NcoI and XhoI restriction sites. The cloning was
carried out at the molecular cloning facility at the Florida State University. The pET32b
enables expression of P43LGRN-3 as a thioredoxin fusion protein, P43LGRN-3-trxA.
Thioredoxin facilitates disulfide bond formation in GRN-3 as the latter has six disulfide
bonds. The pET32b:P43LGRN-3 plasmid was transformed and expressed using E. coli
SHuffle competent cells (NEB). These cells have two distinct advantages: a) they carry
mutations that maintain oxidizing conditions in the cytoplasm, which facilitate disulfide
bond formation and, b) the cells express cytoplasmic disulfide bond isomerase (DsbC)
that further enhances correct disulfide pairing. The cells containing the plasmids,
pET32b:P43LGRN-3 were grown in a 2L baffled culture flasks containing one liter of
LB broth medium supplemented with 100 μg mL-1 of ampicillin. The cells were grown
till the optical density, measured using a UV-vis spectrophotometer at 600 nm, was
between 0.5 – 0.6 AU. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was then added to
a final concentration of 0.1 mM to induce expression of the P43LGRN-3-trxA fusion
protein. The IPTG was added when the optical density of the cells was between 0.5 and
0.7. The cells were harvested after six hours of growth at 30 °C with constant agitation at
250 rpm by centrifuging at 14000xg at 4oC for 10 minutes and were used immediately or
stored at -20oC for later use.
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3.2 Purification of Recombinant P43LGRN-3-trxA
Cell pellets collected from the 2 L culture were thawed at room temperature and
then resuspended in a total of 30-40 mL of equilibration buffer (50mM Tris, 300 mM
NaCl, 10mM imidazole, pH 6.5). The slightly acidic pH was maintained to minimize
potential disulfide bond scrambling. Once resuspended in the buffer, 0.5 mM
phenylmethylsulfonyl fluoride (PMSF) was added to prevent any proteolytic digestion.
The cell suspension was then sonicated for a total of two minutes with 40 seconds bursts
on ice and one minute rest. The suspension was then centrifuged at 9200xg to remove all
cell debris. The supernatant from this step was loaded onto a Ni2+-NTA column that was
pre-equilibrated with the equilibration buffer. The supernatant was rocked with the beads
for one hour at 4oC to ensure maximum binding between nickel beads and the
supernatant. After an hour, the supernatant was loaded onto the column and the flowthrough was collected by gravity elution. The beads were then washed with 200 mL of
wash buffer (50 mM Tris, pH 6.5, 300 mM NaCl, and 120 mM imidazole) to remove
non-specific binding, and eluted using 50 mL of 400 mM imidazole in 50 mM Tris, pH
6.5, and 300 mM NaCl. In order to remove the imidazole, the protein was then dialyzed
using a 10 kDa molecular weight cut-off (MWCO) semi-permeable membrane (Spectrum
labs) at room temperature against a buffer with 2 mM Tris-HCl, pH 6.5, and 5 mM NaCl.
The dialysate was then concentrated using a vacufuge such that the final buffer
concentration was 20 mM Tris, pH 6.2 and 50 mM NaCl. After this, UV-Vis
spectroscopy was used to measure the concentration of the fusion protein using a molar
extinction coefficient of 20355 M-1cm-1 at 280 nm. The concentrated protein was
aliquoted in 1 mL fractions and immediately incubated with restriction grade thrombin

9

Characterization of P43LGrnB

(Novagen) (1U per 2 mg of protein) to cleave P43LGRN-3 from the P43LGRN-3-trxA
fusion protein. The sample was incubated at 37 °C for 22-24 hours. The P43LGRN-3
protein was then fractioned using a semi-preparative Jupiter® 5 μm C18 reverse phase
HPLC column (Phenomenex, CA) with height and internal diameter of 250 mm and 10
mm, respectively, and a gradient of 80 – 60 % acetonitrile containing 0.1% TFA.

3.3 SDS-PAGE, MALDI-ToF and Free Thiol Quantification
The purity of the protein was assessed using SDS-polyacrylamide gel
electrophoresis (PAGE) and MALDI-ToF mass spectrometry (Bruker Daltonics Inc).
SDS- PAGE was performed using 8-16% Mini-Protean precast gels (BioRad). The
protein samples were subjected to reducing or non-reducing 4X Laemmli buffer with and
without boiling. Gels were stained using a Pierce silver staining kit (Thermo Scientific)
and imaged using a GelDoc molecular imager (BioRad).
For MALDI-ToF, one microliter of sinnapinic acid (SA) matrix was mixed with
one microliter of protein sample on a MSP 96 microchip target (Bruker) to yield a final
protein concentration of 0.01-0.1 nM. The SA matrix was made by resuspending 10 mg
of SA in one milliliter of 1:1 acetonitrile:water with 0.1%TFA.
To check the integrity of disulfide bonds, the sample was analyzed by SDS-PAGE
under reducing and non-reducing conditions. Since GRN-3 contains six disulfide bonds,
the integrity of the disulfide bonds was analyzed using Ellman’s assay. This assay uses
Ellman’s reagent [2,2’-dithiobis-(2-nitrobenzoate)] which reacts with free sulfhydryls
(thiols) to form a yellow colored product whose intensity can be estimated by measuring
UV-absorbance at 412 nm and used to calculate the percentage of free cysteines.

10

Characterization of P43LGrnB

Alkylation experiments were also performed on the samples in which 2-4 μg of
P43LGRN-3 was incubated with 2000x molar excess of iodoacetamide solution in
presence of 1000x molar excess of guanidium hydrochloride at room temperature for 90
min to overnight in the dark. Alkylation of the protein was analyzed using MALDI-ToF.

3.4 Fluorescence Spectroscopy
A Cary Eclipse spectrometer (Agilent Inc.) was used to perform fluorescence
measurements. The samples were excited at 280 nm to measure the fluorescent emissions
from intrinsic tryptophan residues within the protein sequence. The excitation and
emission slits were set at 10 or 20 nm. Binding interactions between P43LGRN-3 and Aβ
peptides was assessed using intrinsic fluorescence assay as well. Aβ peptides were
titrated onto P43LGRN-3 and changes in emission spectrum for each titration were
monitored. The sample was excited at 290 nm to avoid excitation of tyrosine residues,
which excite at ~276 nm. The fluorescence was monitored at 350 nm with a bandwidth of
10 nm.

3.5 Circular Dichroism (CD)
To assess the secondary structure, the protein was analyzed using a Jasco J-815
CD spectrometer. Using a 1 mm path length quartz cuvette (Helma), the samples were
monitored under continuous scanning mode from 260 to 198 nm with a scanning speed of
50 nm/min. The data integration time was set at 8 seconds, bandwidth at 1 nm, and data
pitch at 0.1 nm. Each Far-UV CD spectra obtained was representative of an average of
three scans.
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3.6 Interactions of P43LGRN-3 and Aβ
Effects of P43LGRN-3 on Aβ aggregation were analyzed by co-incubating
P43LGRN-3 with Aβ at varying stoichiometric concentrations, and monitoring
aggregation by Thioflavin T (ThT) fluorescence assay, immunoblotting, and circular
dichroism. For the ThT assay, the samples were diluted 15-fold using 10 μM ThT
prepared in 20 mM Tris-HCl, pH 8.0 or 6.5. Fluorescence measurements were taken for 1
minute with excitation and emission wavelengths at 450 and 482 nm, respectively. These
co-incubated samples were also analyzed using SDS-PAGE and immunoblotting in
parallel. For immunoblotting, the co-incubated proteins were transferred from the SDS
gel to 0.45 μm pore size BioTraceTM NT nitrocellulose membrane (PALL Life
Sciences/BioRad) and blocked with 5% non-fat dry milk in 1x standard phosphate
buffered saline (PBS), pH 7.4, with 0.1% Tween 20®. The blots were probed overnight
with an Aβ42 specific antibody and then incubated with a Horse Radish Peroxidase
(HRP)-conjugated secondary antibody for 1-2 hours. The blots were developed with
enhanced chemiluminescence (ECL) substrate for 2 minutes (Thermo Scientific) and
imaged using a GelDoc molecular imager (BioRad).

12

Characterization of P43LGrnB

Chapter 4 - Results
4.1 Recombinant Expression of P43LGRN-3
4.1.1 Transformation and Purification
The pET32b:P43LGRN-3 plasmid was transformed into SHuffle competent E.
coli cells using the heat shock method. The protein was expressed on a small scale (7 mL
culture). Both induced and un-induced cultures were electrophoresed under reducing
conditions on a 4-20% SDS-PAGE gel. An intense band, which is more prominent in the
induced than the un-induced samples, is present at approximately 20 kDa as indicated by
the arrow. (Figure 2). This corresponds to the 20.3 kDa molecular weight of P43LGRN3-trxA protein. The protein expression was later scaled up to 1L cultures and purified as
described in the Materials and Methods section.

Figure 2: Small scale expression of P43LGRN-3-trxA in SHuffle E. coli cells
containing the pET32b:P43LGRN-3 plasmid, analyzed on 4-20% SDS-PAGE gel. Both
induced (+) and un-induced (U) colonies exhibit band under 20 kDa (highlighted with
arrow). Band is darker in induced lanes.
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To confirm the presence of the P43LGRN-3-trxA protein, aliquots from each step
of the purification (pellet, supernatant, flow-through, wash 1, wash 2, and strip) were
taken and subjected to
electrophoresis on a 4- 20%
SDS-PAGE gel (Figure 3). An
intense band seen in the elution
fraction at approximately 6
kDa confirmed the presence of
the target protein. The eluate
was then dialyzed and the
concentration was calculated
using a UV-Vis spectrometer.
Prior to HPLC, thrombin
Figure 3: Ni-NTA Purification of thioredoxin
fusion protein. In the elution lane, a dark band,
highlighted by the arrow, indicates the presence
of P43LGRN-3-trxA.

digestion was performed to
separate the P43LGRN-3
protein from its thioredoxin

fusion.
4.1.2 HPLC Analysis
P43LGRN-3 monomer was isolated using a reverse phase C-18 HPLC column
with a gradient of 80-60% acetonitrile with 0.1 % TFA. The resulting HPLC profile for
P43LGRN-3 can be seen in Figure 4A. Peaks have been labeled with their corresponding
fraction number. Fraction 46 is suspected to be the monomeric fraction as indicated by
the (M) above the peak. Figure 4B shows the HPLC profile of the wild-type GRN-3
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protein, in which Fraction 48 corresponds to monomeric GRN-3. It is noteworthy that the
fractionation profile of P43LGRN-3 indicated that the mutant is able to generate a
significantly lesser degree of multimeric GRN-3 as compared to the wild-type protein
(Figure 4A and B). This could indicate that the P43L mutation is able to limit disulfide
bond scrambling during expression, resulting in a decrease in the amount of multimers.

B

A

Figure 4: HPLC Profiles. A- P43LGRN3 monomer elutes in fraction 46 and forms
far less multimers than does GRN-3. B- Native GRN-3 monomer elutes at fraction 48
and forms extensive multimers.

4.2 Characterization of the protein
4.2.1 SDS PAGE Analysis
Selected fractions from the HPLC were run on an 8-16% SDS-PAGE gel under
reducing and non-reducing conditions (Figure 5). All lanes showed an intense band
between 3.5 and 10 kDa corresponding to the 6.3 kDa molecular weight of monomeric
P43LGRN-3. Many lanes, both reduced and non-reduced, also presented extensive
banding and smearing, indicating that P43LGRN-3 forms disulfide-bonded multimers.

15

Characterization of P43LGrnB

Lanes 1 and 2, represent the reduced and non-reduced samples of HPLC fraction 46 that
differ from the other lanes in that the non-reduced lane showed a negligible amount of
multimers except for a faint dimeric band, which we conclude is the intramolecularly
disulfide bonded monomer.

Figure 5: SDS-PAGE (8-16%) analysis of
HPLC fractions. Fraction 46 shows minimal
banding in both lanes.

4.2.2 MALDI-ToF Mass Spectrometry
To conclusively identify the monomeric fraction, selected fractions were analyzed
using MALDI-ToF mass spectrometry. The profiles can be seen in Figure 6A-B. In the
fraction 46 spectra, there was an intense peak of molecular weight 6375.29 Da
corresponding to the molecular weight of monomeric P43LGRN-3. There was also a
relatively small dimeric peak, corroborating the faint band seen on the SDS-PAGE gel
image. When compared to spectra obtained from the analysis of other fractions, it was
clear that the ratio for monomer to dimer was much higher in the multimeric fraction and
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that the peaks corresponding to higher-level multimers were absent. This confirmed that
fraction 46 was indeed the monomeric P43LGRN-3 fraction.

A

B

Figure 6: MALDI-ToF spectra. A- P43LGRN-3 fraction 46 exhibits an intense monomeric
peak of molecular weight 63675.29 Da and a relatively small dimeric peak. B- Fraction 57
shows a much higher relative ratio of monomer to dimer as well as several other multimers.

4.2.3 Ellman’s Assay
Using Ellman’s Assay, the percentage of free cysteines present in the monomeric
and multimeric HPLC fractions was found. The monomeric fraction showed that
approximately 1% (0.8%) of the cysteines was free. This low percentage suggests that all
six disulfide bonds were present and that the protein was in its completely oxidized state.
The percentage of free cysteines in the multimeric fraction was zero.

4.2.4 Circular Dichroism
Monomeric P43LGRN-3 was also subjected to CD spectroscopy analysis. The
spectra exhibited a minimum at ~200 nm, which is characteristic of random coil structure

17

Characterization of P43LGrnB

(Figure 7A). This minimum could also be seen in the CD spectra of wild-type GRN-3
(Figure 7B). However, some spectral difference existed between the mutant and wildtype, namely the slight maximum that is seen at ~230 nm in the P43LGRN-3 spectra.
This maximum was absent in the wild-type protein, which could suggest that the mutant
form exhibited characteristics of a poly proline type II helix (PPII). Random coil
structures and PPII helices share similar arrangement of amide dipoles and, as such, both
are commonly observed conformations for IDPs.

A

B
Figure 7: CD Spectra. A- P43LGRN-3 exhibits a random coil structure with
characteristic minima at approximately 200 nm. B- Wild-type GRN-3 also exhibits
random coil structure. No appreciable differenced exist between the profiles.

4.2.5 Intrinsic Tryptophan Fluorescence
To investigate whether P43LGRN-3 was forming non-covalent dimers as seen in
the non-reduced monomeric lane on the SDS-PAGE gel (refer to Figure 5), tryptophan
fluorescence was monitored as a function of protein concentration. Any change in W
fluorescence with dilution can be correlated to formation of dimers via non-covalent
interactions such as hydrophobic interactions. Upon dilution and normalization of data,
an exponential response was seen in the P43LGRN-3 sample (Figure 8). Conversely, the
negative control, performed with bovine serum albumin (BSA), did not show an
18
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exponential response, indicating that the changes in tryptophan fluorescence were unique
to P43LGRN-3. These data provided indirect evidence that P43LGRN-3 does form noncovalent dimers.

Figure 8: Tryptophan Fluorescence. An exponential
response is seen with P43LGRN-3. The negative
control shows no such response.

4.3 P43LGRN-3 Interactions with wt-Aβ42
4.3.1 P43LGRN-3 and wt-Aβ42 Co-incubations
Freshly purified wt-Aβ42 (20 μM ) was co-incubated with 4 μM
(substoichiometric) and 40 μM (superstoichiometric) concentrations of P43LGRN-3.
Aggregation of Aβ was monitored using ThT fluorescence and western immunoblotting
with a primary antibody specific for Aβ. Figure 9 shows the ThT data plotted over a
period of 50 hours. The data shows that substoichiometric concentrations of P43LGRN-3
did not have an appreciable effect on the initial aggregation of Aβ. However,
superstoichiometric incubation exhibited a drastic acceleration in aggregation within the
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first 36 hours of incubation. A superstoichiometric concentration of wild-type GRN-3
was also included in the experiment. As seen in the figure, the effect of wild-type GRN-3
and P43LGRN-3 on Aβ aggregation were similar.

Figure 9: ThT Co-incubation Data. A drastic acceleration in
aggregation of Aβ is seen with 40 μM P43LGRN-3 and wild-type GRN-3.

The co-incubation was also monitored using ThT fluorescence via western
immunoblotting at the 6 and 12 hour time points (Figure 10). After 6 hours, Lane 3,
which corresponds to Aβ incubated with 40 μM P43LGRN-3, showed a high molecular
weight aggregate. This indicates that within 6 hours, P43LGRN-3 was causing Aβ to
aggregate into fibrils. The same pattern can also be seen after 12 hours. No such
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aggregate was seen in the Aβ control lane or the lane with Aβ incubated with 4 μM
P43LGRN-3. The 40 μM wild-type GRN-3 incubated with Aβ, seen in lane 4, behaved
similarly to 40 μM P43LGRN-3, exhibiting a high molecular weight aggregate after 6
hours.

Figure 10: Western Immunoblots (6 hr and 12 hr) A high
molecular weight band is seen in the 40 μM lane of
P43LGRN-3 after 6 hours. The same can be seen in lane 4 (40
μM GRN-3) after 6 hours. 12 hr blot shows same activity.
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Chapter 5 – Conclusions
5.1 P43LGRN3 Conclusions
Amyloid-β aggregation is known to be a primary causative agent in the onset and
progression of AD, yet the molecular underpinnings of the pathology remain unclear.
Emerging evidence suggests that acute neuroinflammation could trigger initial Aβ
aggregation. Our hypothesis that granulins could be a key modulator of inflammation and
dementia is due to their pro-inflammatory nature and roles in neurodegenerative
disorders. Both wt and P43LGRN-3 have been implicated in FTD, and hence are of
particular interest in our laboratory.
The primary objective of my research was to identify the effect of the P43L
mutation on the structure and/or function of the protein as compared to the wt GRN-3. In
this context, our findings have revealed several shared characteristics between the mutant
and the wt GRN-3. Structurally, both proteins are largely disordered, with P43LGRN-3
CD spectra revealing a random coil structure with possible PPII helical content (which is
also a trait of intrinsically disordered proteins (IDPs). Although similar to each other in
many biophysical aspects, wt and mutant GRN-3 differ in their expression of monomeric
and multimeric forms. While wt GRN-3 seems to generate more multimers, P43LGRN-3
showed markedly reduced levels of multimers by HPLC fractionation (Fig 4A-B). It is
unknown whether the presence of the PPII helix is responsible for the marked decrease in
the formation of multimers seen on comparison of mutant and wild-type HPLC profiles.
Furthermore, the physiological implications of these findings are yet to be determined.
Lastly, through tryptophan fluorescence, we indirectly determined that P43LGRN-3
forms non-covalent dimers. The significance of this finding may perhaps be found in its
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structural implication for the PGRN protein. Recent studies have provided evidence
suggesting that the majority of secreted and circulating PGRN exists as a homodimer, but
the regions required for homodimerization to occur are not known. The functional
relevance of formation of Progranulin dimers is currently unknown. From a functionality
standpoint, both wild-type and mutant GRN-3 have been shown to accelerate the
aggregation of Aβ into fibrils. This behavior, though not unique to the P43L mutant,
supports our hypothesis that Granulins, specifically GRN-3, are capable of interacting
with extracellular Aβ, facilitating its aggregation, and thereby modulating the onset of
inflammation-induced AD.
Our research suggests that the P43L mutation has a minimal effect on the
structure and function of the GRN-3 protein, although the mutation seems to minimize
the levels of intermolecularly disulfide-bonded multimers in the protein.
5.2 Future Directions
Although no differences in structure or function between the wt and mutant
P43LGRN-3 were discovered in this research, we have not yet explored the effect of the
P43L mutation on the full-length Progranulin structure. It is plausible that the presence
of leucine is pathogenic due to its destabilization of the Progranulin structure and that it
does not alter the smaller GRN-3 structure and function. This possibility will continue to
be explored as this research is continued. In addition, the propensity for native GRN-3 to
form extensive multimers not seen in the P43LGRN3 purification will be investigated, as
this could indicate an intrinsic difference in the behavior of the two proteins.
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